267 results on '"Mueller, Martin C"'
Search Results
2. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
3. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial
4. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
5. Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel
6. Response-Related Predictors of Survival in CML
7. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
8. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV
9. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
10. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
11. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells
12. The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia
13. Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia
14. Modelling ROTASTORE — A Highly Parallel, Short Term Storage System
15. Standardization of molecular monitoring of CML : results and recommendations from the European treatment and outcome study
16. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
17. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
18. BCR-ABL Mutations in Chronic Myeloid Leukemia
19. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA
20. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
21. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
22. Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation
23. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
24. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up
25. Cause and management of therapy resistance
26. Exogenous reelin prevents granule cell dispersion in experimental epilepsy
27. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity
28. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
29. CML-310 Early Cytogenetic or Molecular Landmark Response to Ponatinib Treatment Predicts Outcomes in Heavily Pretreated Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in PACE: 5-Year Data
30. POSTER: CML-310 Early Cytogenetic or Molecular Landmark Response to Ponatinib Treatment Predicts Outcomes in Heavily Pretreated Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in PACE: 5-Year Data
31. Resistance to Targeted Therapy in Chronic Myelogenous Leukemia
32. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications
33. ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis
34. Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia
35. The Vascular Bone Marrow Niche Influences Outcome in Chronic Myeloid Leukemia
36. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI) : a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
37. Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial
38. 5-Year Updates from the Pivotal Phase 2 Ponatinib PACE Trial: Efficacy, Safety and Landmark Analysis in Heavily Pretreated Patients with Chronic-Phase Chronic Myeloid Leukemia
39. Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial
40. Novel Fusion Genes at CML Diagnosis Reveal a Complex Pattern of Genomic Rearrangements and Sequence Inversions Associated with the Philadelphia Chromosome in Patients with Early Blast Crisis
41. Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA
42. High BCR-ABL/GUSIS Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib
43. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias
44. Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
45. Sample Exchange to Standardize Molecular Monitoring for CML: The EUTOS Experience
46. Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study
47. Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase
48. What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?
49. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis
50. What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.